Sarepta Therapeutics Share Price (NASDAQ: SRPT)

$18.22

▲

-0.12

(-0.65%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Sarepta Therapeutics Stock chart to analyse performance

Sarepta Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$17.80
Today's High:$18.63
$18.22
2.31%
Downside
Day's Volatility :4.46%
Upside
2.2%
52 Weeks Low:$10.42
52 Weeks High:$138.81
$18.22
42.84%
Downside
52 Weeks Volatility :92.5%
Upside
86.87%

Sarepta Therapeutics Stock Returns

Period	Sarepta Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-51.7%	3.6%	0.0%
6 Months	-81.99%	-7.7%	0.0%
1 Year	-86.51%	-12.6%	0.0%
3 Years	-83.44%	9.5%	-4.7%

Sarepta Therapeutics, Inc. Key Stats

Check Sarepta Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$18.34
Open	$18.32
Today's High	$18.63
Today's Low	$17.8
Market Capitalization	$1.8B
Today's Volume	$22.5M
52 Week High	$138.81
52 Week Low	$10.415
Revenue TTM	$2.5B
EBITDA	$40.1M
Earnings Per Share (EPS)	$-0.68
Profit Margin	-2.34%
Quarterly Earnings Growth YOY	26.64%
Return On Equity TTM	-4.76%

Stock Returns calculator for Sarepta Therapeutics Stock including INR - Dollar returns

The Sarepta Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Sarepta Therapeutics investment value today

Current value as on today

₹18,770

Returns

₹81,230

(-81.23%)

Returns from Sarepta Therapeutics Stock

₹86,514 (-86.51%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Sarepta Therapeutics Stock

-62.36%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Investment in Sarepta Therapeutics Shares from India has dropped by -62.36% over the past 30 days, indicating reduced transactional activity.

29%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Sarepta Therapeutics Stock from India on INDmoney has increased by 29% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Sarepta Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
10.14%
Vanguard Group Inc
9.38%
D. E. Shaw & Co LP
4.58%
State Street Corp
4.16%
Wellington Management Company LLP
2.59%
Farallon Capital Management, L.L.C.
2.40%

Analyst Recommendation on Sarepta Therapeutics Stock

Rating

Trend

Buy

82%Buy

17%Hold

0%Sell

Based on 29 Wall street analysts offering stock ratings for Sarepta Therapeutics(by analysts ranked 0 to 5 stars)

Sarepta Therapeutics Share Price Target

What analysts predicted

Upside of 30.85%

Target:

$23.84

Current:

$18.22

Sarepta Therapeutics share price target is $23.84, a slight Upside of 30.85% compared to current price of $18.22 as per analysts' prediction.

Sarepta Therapeutics Stock Insights

Price Movement
In the last 7 days, SRPT stock has moved down by -9.8%
Decreasing Revenue
Revenue is down for the last 2 quarters, 744.85M → 611.09M (in $), with an average decrease of 18.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -447.50M → 196.89M (in $), with an average increase of 327.3% per quarter
SRPT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 156.5%
SRPT vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 195.9%
Price to Sales
ForSRPT every $1 of sales, investors are willing to pay $0.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Sarepta Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$380.8M	↑ 26.51%
Net Income	$-715.1M	↑ 97.58%
Net Profit Margin	-187.77%	↓ 67.55%

	FY20	Y/Y Change
Revenue	$540.1M	↑ 41.82%
Net Income	$-554.1M	↓ 22.51%
Net Profit Margin	-102.6%	↑ 85.17%

	FY21	Y/Y Change
Revenue	$701.9M	↑ 29.96%
Net Income	$-418.8M	↓ 24.43%
Net Profit Margin	-59.66%	↑ 42.94%

	FY22	Y/Y Change
Revenue	$933.0M	↑ 32.93%
Net Income	$-703.5M	↑ 67.99%
Net Profit Margin	-75.4%	↓ 15.74%

	FY23	Y/Y Change
Revenue	$1.2B	↑ 33.26%
Net Income	$-536.0M	↓ 23.81%
Net Profit Margin	-43.11%	↑ 32.29%

	FY24	Y/Y Change
Revenue	$1.9B	↑ 52.97%
Net Income	$235.2M	↓ 143.89%
Net Profit Margin	12.37%	↑ 55.48%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$413.5M	↑ 4.2%
Net Income	$36.1M	↓ 20.89%
Net Profit Margin	8.74%	↓ 2.77%

	Q2 FY24	Q/Q Change
Revenue	$362.9M	↓ 12.22%
Net Income	$6.5M	↓ 82.11%
Net Profit Margin	1.78%	↓ 6.96%

	Q3 FY24	Q/Q Change
Revenue	$467.2M	↑ 28.72%
Net Income	$33.6M	↑ 420.29%
Net Profit Margin	7.19%	↑ 5.41%

	Q4 FY24	Q/Q Change
Revenue	$658.4M	↑ 40.94%
Net Income	$159.0M	↑ 373.21%
Net Profit Margin	24.16%	↑ 16.97%

	Q1 FY25	Q/Q Change
Revenue	$744.9M	↑ 13.13%
Net Income	$-447.5M	↓ 381.36%
Net Profit Margin	-60.08%	↓ 84.24%

	Q2 FY25	Q/Q Change
Revenue	$611.1M	↓ 17.96%
Net Income	$196.9M	↓ 144.0%
Net Profit Margin	32.22%	↑ 92.3%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$324.2M	↑ 21.51%

	FY20	Y/Y Change
Profit	$476.7M	↑ 47.02%

	FY21	Y/Y Change
Profit	$604.8M	↑ 26.88%

	FY22	Y/Y Change
Profit	$793.0M	↑ 31.11%

	FY23	Y/Y Change
Profit	$1.1B	↑ 37.83%

	FY24	Y/Y Change
Profit	$1.6B	↑ 44.82%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$362.9M	↑ 2.92%

	Q2 FY24	Q/Q Change
Profit	$309.7M	↓ 14.67%

	Q3 FY24	Q/Q Change
Profit	$375.5M	↑ 21.25%

	Q4 FY24	Q/Q Change
Profit	$526.1M	↑ 40.12%

	Q1 FY25	Q/Q Change
Profit	$607.3M	↑ 15.43%

	Q2 FY25	Q/Q Change
Profit	$447.7M	↓ 26.28%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-456.5M	↑ 17.45%
Investing Cash Flow	$286.7M	↓ 177.39%
Financing Cash Flow	$642.6M	↑ 21.2%

	FY20	Y/Y Change
Operating Cash Flow	$107.5M	↓ 123.54%
Investing Cash Flow	$-121.7M	↓ 142.45%
Financing Cash Flow	$682.3M	↑ 6.19%

	FY21	Y/Y Change
Operating Cash Flow	$-443.2M	↓ 512.38%
Investing Cash Flow	$495.4M	↓ 507.01%
Financing Cash Flow	$561.6M	↓ 17.7%

	FY22	Y/Y Change
Operating Cash Flow	$-325.3M	↓ 26.59%
Investing Cash Flow	$-1.0B	↓ 311.32%
Financing Cash Flow	$232.5M	↓ 58.6%

	FY23	Y/Y Change
Operating Cash Flow	$-501.0M	↑ 53.99%
Investing Cash Flow	$-165.8M	↓ 84.16%
Financing Cash Flow	$125.0M	↓ 46.24%

	FY24	Y/Y Change
Operating Cash Flow	$-205.8M	↓ 58.92%
Investing Cash Flow	$755.6M	↓ 555.7%
Financing Cash Flow	$124.8M	↓ 0.16%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-242.1M	↑ 342.9%
Investing Cash Flow	$218.8M	↓ 439.97%
Financing Cash Flow	$22.1M	↑ 1039.48%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$14.9M	↓ 106.17%
Investing Cash Flow	$-98.5M	↓ 145.03%
Financing Cash Flow	$39.9M	↑ 80.3%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-70.7M	↓ 573.16%
Investing Cash Flow	$-128.8M	↑ 30.75%
Financing Cash Flow	$13.8M	↓ 65.54%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$92.0M	↓ 230.19%
Investing Cash Flow	$764.1M	↓ 693.14%
Financing Cash Flow	$49.0M	↑ 256.12%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-583.4M	↓ 733.85%
Investing Cash Flow	$-291.2M	↓ 138.11%
Financing Cash Flow	$12.5M	↓ 74.54%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$261.3M	↓ 144.79%
Investing Cash Flow	$32.2M	↓ 111.06%
Financing Cash Flow	$-23.8M	↓ 290.98%

Sarepta Therapeutics Technicals Summary

Sell

Neutral

Buy

Sarepta Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Sarepta Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Sarepta Therapeutics, Inc.	11.02%	-81.99%	-86.51%	-83.44%	-87.17%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Sarepta Therapeutics, Inc.	27.21	NA	159.25	-1.73	-0.05	0.0	NA	13.89
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Sarepta Therapeutics, Inc.	Buy	$1.8B	-87.17%	27.21	-2.34%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Organization	Sarepta Therapeutics
Employees	1372
CEO	Mr. Douglas S. Ingram Esq., J.D.
Industry	Health Technology

Key Management of Sarepta Therapeutics, Inc.

Name	Title
Mr. Douglas S. Ingram Esq., J.D.	CEO & Director
Mr. Ian Michael Estepan	President & COO
Dr. Louise R. Rodino-Klapac Ph.D.	President of Research & Development and Technical Operations
Mr. Bilal Arif	Special Advisor
Ryan H. Wong	Executive VP & CFO
Rachael Potter Ph.D.	Chief Scientific Officer
Ms. Francesca T. Nolan	Executive Director of Investor Relations and Corporate Communications
Ms. Cristin L. Rothfuss J.D.	Executive VP, Chief General Counsel & Corporate Secretary
Ms. Alison Nasisi	Executive VP & Chief People Officer
Dr. Diane L. Berry Ph.D.	Executive VP and Chief of Global Policy & Advocacy Officer

Important FAQs about investing in SRPT Stock from India :

What is Sarepta Therapeutics share price today?

Sarepta Therapeutics share price today is $18.22 as on August 30, 2025 at 1:29 am IST at the close of the market. Sarepta Therapeutics share today touched a day high of $18.63 and a low of $17.80.

What is the 52 week high and 52 week low for Sarepta Therapeutics share?

Sarepta Therapeutics share touched a 52 week high of $138.81 and a 52 week low of $10.42. Sarepta Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $18.22, lower by 86.87% versus the 52 week high.

How to invest in Sarepta Therapeutics Stock (SRPT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Sarepta Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sarepta Therapeutics Shares that will get you 0.0823 shares as per Sarepta Therapeutics share price of $18.22 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Sarepta Therapeutics Stock (SRPT) from India?

Indian investors can start investing in Sarepta Therapeutics (SRPT) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Sarepta Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Sarepta Therapeutics share’s latest price of $18.22 as on August 30, 2025 at 1:29 am IST, you will get 0.5488 shares of Sarepta Therapeutics. Learn more about fractional shares .

What are the returns that Sarepta Therapeutics has given to Indian investors in the last 5 years?

Sarepta Therapeutics stock has given -87.17% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?